Linagliptin Impurity 26, identified by its CAS number 2446799-71-7, is a chemical compound that serves as an impurity associated with the pharmaceutical agent Linagliptin, which is used in the treatment of type 2 diabetes. While specific characteristics such as molecular weight, structure, and solubility may not be widely documented in public databases, impurities like this are typically characterized by their potential impact on the efficacy and safety of the primary drug. Impurities can arise during the synthesis of pharmaceuticals and may affect the drug's stability, bioavailability, and overall therapeutic profile. In the context of quality control, understanding the properties of such impurities is crucial for regulatory compliance and ensuring the safety of the final pharmaceutical product. Analytical techniques such as HPLC, NMR, and mass spectrometry are often employed to identify and quantify impurities in drug formulations. As with any chemical substance, handling should adhere to safety guidelines to mitigate any potential risks associated with exposure.

Linagliptin Impurity 26

2446799-71-7: Linagliptin Impurity 26, identified by its CAS number 2446799-71-7, is a chemical compound that serves as an impurity associated with the pharmaceutical agent Linagliptin, which is used in the treatment of type 2 diabetes. While specific characteristics such as molecular weight, structure, and solubility may not be widely documented in public databases, impurities like this are typically characterized by their potential impact on the efficacy and safety of the primary drug. Impurities can arise during the synthesis of pharmaceuticals and may affect the drug's stability, bioavailability, and overall therapeutic profile. In the context of quality control, understanding the properties of such impurities is crucial for regulatory compliance and ensuring the safety of the final pharmaceutical product. Analytical techniques such as HPLC, NMR, and mass spectrometry are often employed to identify and quantify impurities in drug formulations. As with any chemical substance, handling should adhere to safety guidelines to mitigate any potential risks associated with exposure.

CAS 2446799-71-7

Linagliptin Impurity 26

Linagliptin Impurity 30

Ref: 4Z-L-4451